The rise of Sildenafil initially fueled a period of growth for major pharmaceutical companies, nevertheless recent changes present a uncertain scenario for investors. Generic competitors are eroding earnings, and persistent legal battles add additional complexity to the equation. While some companies might still gain from related products, the over